Recon: FDA greenlights Seres’ oral microbiome drug; Bristol Myers names new CEO as generic competition rises
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy